Indication
Adrenocortical Cancer
16 clinical trials
18 products
5 drugs
Clinical trial
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid TumoursStatus: Recruiting, Estimated PCD: 2024-06-01
Product
[225Ac]-FPI-1434Product
FPI-1175Product
FPI-1547Clinical trial
A Phase 1b, Open-Label Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid ProductionStatus: Completed, Estimated PCD: 2023-10-17
Product
RelacorilantProduct
PembrolizumabProduct
[225Ac]-FPI-1434 InjectionProduct
68Ga-R8760Clinical trial
Phase 1 Safety and Dosimetry Study of 68Ga-R8760 in Patients With Adrenocortical Carcinoma and Healthy VolunteersStatus: Recruiting, Estimated PCD: 2024-04-01
Product
RAIN-32Clinical trial
A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors (MANTRA-2)Status: Terminated, Estimated PCD: 2023-10-15
Clinical trial
A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/ParagangliomaStatus: Active (not recruiting), Estimated PCD: 2024-05-30
Product
NivolumabProduct
EO2401Clinical trial
Dostarlimab as First-line Treatment for Patients With dMMR/MSI (Non-colorectal/Non-endometrial) Locally Advanced or Metastatic Cancer: a Randomized Phase 2 Trial (Cohort Pan-MSI ACSE) With Crossover in the Standard Arm at ProgressionStatus: Not yet recruiting, Estimated PCD: 2028-10-01
Product
DostarlimabDrug
CisplatinClinical trial
Phase 1 Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid TumorsStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Prospective Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma After Failure of Platinum- and Mitotane-Based ChemotherapyStatus: , Estimated PCD: 2025-08-31
Product
Pembrolizumab + LenvatinibClinical trial
A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
IpilimumabDrug
T-VECDrug
cyclophosphamideDrug
fludarabineClinical trial
A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical CarcinomaStatus: Recruiting, Estimated PCD: 2026-01-01
Product
MitotaneDrug
mFOLFOX6Clinical trial
Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical CarcinomaStatus: Recruiting, Estimated PCD: 2025-12-01
Product
Sodium thiosulfateClinical trial
Safety and Immunological Effects of Ablative Radiotherapy Followed by Pembrolizumab in Patients With Advanced Adrenocortical CarcinomaStatus: Recruiting, Estimated PCD: 2026-09-27
Clinical trial
Prospective, Phase II Study to Evaluate the Efficacy of Addition of Progesterone to Standard Chemotherapy According to Etoposide-Doxorubicin-Cisplatin Scheme Plus Mitotane (EDP-M) in Patients With Advanced Adrenocortical Carcinoma (ACC)Status: Recruiting, Estimated PCD: 2027-06-08
Clinical trial
A Multicentre, Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.Status: Recruiting, Estimated PCD: 2027-05-31
Clinical trial
The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical CarcinomaStatus: Completed, Estimated PCD: 2023-01-30
Clinical trial
A Phase II Clinical Trial of Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical CarcinomaStatus: Active (not recruiting), Estimated PCD: 2019-01-11